
NICE has refused to back Roche’s Avastin for use in breast cancer patients citing the blockbuster drug’s high cost and …
The chief executive of NICE acknowledges changes are needed in how drugs are assessed in the UK – including more …
Three pharma companies are taking part in a new pilot to harmonise European standards in health technology assessment (HTA). AstraZeneca, …

